Supplemental Table 3 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Autor: Heather A. Wakelee, Christine M. Lovly, Allison Holzhausen, James J. Gibbons, Chris Liang, Kimberly Harrow, Gary Dukart, Jon P. Gockerman, Joel W. Neal, Liping Du, Jennifer G. Whisenant, Rachel E. Sanborn, Barbara J. Gitlitz, Saiama N. Waqar, Ticiana A. Leal, George R. Blumenschein, Karen L. Reckamp, Jeffrey R. Infante, Leora Horn
Rok vydání: 2023
DOI: 10.1158/1078-0432.22464930
Popis: The key pharmacokinetic (PK) parameters (Supplemental Table 3) at the recommended phase 2 dose of 225 mg show that food has minimal impact on absorption of ensartinib.
Databáze: OpenAIRE